Supernus Pharmaceuticals (LTS:0LB2) Growth Rank: 3 (As of Aug. 10, 2026) — 50% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0LB2 Supernus Pharmaceuticals Inc LTS:0LB2
78 GF Score
Price $47.03
GF Value $43.68
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Supernus Pharmaceuticals Growth Rank?

Supernus Pharmaceuticals LTS:0LB2 -0.80% 78 Growth Rank is 3 as of Aug. 10, 2026, which is 50% below its 10-year median of 6.00. GuruFocus rates LTS:0LB2 with a GF Score™ of 78/100 and a GF Value™ of $43.68 (Fairly Valued). The stock has 1 warning sign investors should review.

Supernus Pharmaceuticals has the Growth Rank of 3.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Supernus Pharmaceuticals Growth Rank Related Terms

LTS:0LB2 vs RGC, BCRX, PBH: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Supernus Pharmaceuticals Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Growth Rank distribution charts can be found below:

* The bar in red indicates where Supernus Pharmaceuticals's Growth Rank falls into.


LTS:0LB2
78GF Score
Supernus Pharmaceuticals Inc LTS:0LB2
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 3 mean?
Supernus Pharmaceuticals (LTS:0LB2) has a Growth Rank of 3 as of Aug. 10, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Supernus Pharmaceuticals and its competitors. This is 50% below median its historical median of 6.00. Over the past decade, Supernus Pharmaceuticals' Growth Rank has ranged from 3.00 to 10.00.
Is Supernus Pharmaceuticals' Growth Rank too high?
Supernus Pharmaceuticals' current Growth Rank of 3 is 50% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 10.00. Overall, Supernus Pharmaceuticals has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' Growth Rank compare to RGC and BCRX?
Supernus Pharmaceuticals' Growth Rank of 3 can be compared against companies in the Drug Manufacturers industry. Historically, Supernus Pharmaceuticals' own Growth Rank has ranged from 3.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Supernus Pharmaceuticals and its competitors. Supernus Pharmaceuticals's current Growth Rank is 3, which is 50% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Fairly Valued. The stock's GF Value™ is $43.68, compared to a current price of $47.03 — trading 7.7% above its estimated fair value. The current Growth Rank is 3, which is 50% below median its 10-year median of 6.00. Supernus Pharmaceuticals' overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current Growth Rank is 3 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?

Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued. The current stock price of $47.03 is trading 7.7% above its estimated GF Value™ of $43.68. GuruFocus considers Supernus Pharmaceuticals to be Fairly Valued.

Key valuation signals for LTS:0LB2:

  • Growth Rank: 3 (50% below median its 10-year median of 6.00)
  • GF Value™: $43.68 vs. price of $47.03 (7.7% above fair value)
  • GF Score™: 78/100 with 1 warning sign

No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Supernus Pharmaceuticals Business Description

Other Exchanges SUPN:USAS49:Germany
Address 9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
78GF Score

Get the complete analysis for LTS:0LB2

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$47.03
Price
$43.68
GF Value